







an Open Access Journal by MDPI

Metabolomics Biomarkers for Rehabilitation Outcomes in Neurodegenerative Diseases

Guest Editors:

Dr. Paolo Bongioanni

Dr. Renata Del Carratore

Dr. Andrea Diana

Dr. Cristina Dolciotti

Deadline for manuscript submissions:

closed (31 May 2024)

Message from the Guest Editors

The principal topic of this Special Issue is to explore the impact of fluid biomarkers, and proteomic and metabolomic profiles, as indicators predicting outcome or individuating specific treatment needs during the rehabilitation of patients with neurodegenerative diseases.

The identification of biomarkers, as well as the investigation of proteomic and metabolomic profiling in order to highlight the specific treatment response of patients who have survived stroke or are suffering from a chronic neurological disorder, is currently one of the major topics in neurodegenerative diseases. Indeed, based on their detection, the fluid biomarkers are objectively measurable and evaluable potential indicators predicting not only the disease progression, but also both pharmacological and non-pharmacological treatment responses. Similarly, the examination of specific assays recently provided a metabolomic signature highly predictive of Parkinson's disease and Alzheimer's disease.













an Open Access Journal by MDPI

Editor-in-Chief

Dr. Amedeo Lonardo

1. Formerly Director of the Simple Operating Unit "Metabolic Syndrome", Azienda Ospedaliero-Universitaria, 41126 Modena, Italy 2. Formerly Professor of Internal Medicine, School of Specialization of Allergology and Clinical Immunology, University of Modena and Reggio Emilia, 41121 Modena, Italy

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies shown utility for elucidating have mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Biochemistry & Molecular Biology*) / CiteScore - Q2 (*Endocrinology, Diabetes and Metabolism*)

Contact Us